179 related articles for article (PubMed ID: 7707929)
1. Experimental challenge for the treatment of Duchenne muscular dystrophy using a vascularized free muscle graft.
Dohi D; Ikuta Y; Ishida O; Kimori K; Kuroki H
Microsurgery; 1994; 15(12):871-6. PubMed ID: 7707929
[TBL] [Abstract][Full Text] [Related]
2. Expression and localization of protein inhibitor of neuronal nitric oxide synthase in Duchenne muscular dystrophy.
Guo Y; Petrof BJ; Hussain SN
Muscle Nerve; 2001 Nov; 24(11):1468-75. PubMed ID: 11745948
[TBL] [Abstract][Full Text] [Related]
3. Direct observation of failing fibers in muscles of dystrophic mice provides mechanistic insight into muscular dystrophy.
Claflin DR; Brooks SV
Am J Physiol Cell Physiol; 2008 Feb; 294(2):C651-8. PubMed ID: 18171725
[TBL] [Abstract][Full Text] [Related]
4. Disodium cromoglycate protects dystrophin-deficient muscle fibers from leakiness.
Marques MJ; Ventura Machado R; Minatel E; Santo Neto H
Muscle Nerve; 2008 Jan; 37(1):61-7. PubMed ID: 17724738
[TBL] [Abstract][Full Text] [Related]
5. Independent localization of dystrophin N- and C-terminal regions to the sarcolemma of mdx mouse myofibres in vivo.
Dunckley MG; Wells KE; Piper TA; Wells DJ; Dickson G
J Cell Sci; 1994 Jun; 107 ( Pt 6)():1469-75. PubMed ID: 7962190
[TBL] [Abstract][Full Text] [Related]
6. Revertant fibres: a possible genetic therapy for Duchenne muscular dystrophy?
Wilton SD; Dye DE; Blechynden LM; Laing NG
Neuromuscul Disord; 1997 Jul; 7(5):329-35. PubMed ID: 9267847
[TBL] [Abstract][Full Text] [Related]
7. Successful histocompatible myoblast transplantation in dystrophin-deficient mdx mouse despite the production of antibodies against dystrophin.
Vilquin JT; Wagner E; Kinoshita I; Roy R; Tremblay JP
J Cell Biol; 1995 Nov; 131(4):975-88. PubMed ID: 7490298
[TBL] [Abstract][Full Text] [Related]
8. Unacylated Ghrelin Enhances Satellite Cell Function and Relieves the Dystrophic Phenotype in Duchenne Muscular Dystrophy mdx Model.
Reano S; Angelino E; Ferrara M; Malacarne V; Sustova H; Sabry O; Agosti E; Clerici S; Ruozi G; Zentilin L; Prodam F; Geuna S; Giacca M; Graziani A; Filigheddu N
Stem Cells; 2017 Jul; 35(7):1733-1746. PubMed ID: 28436144
[TBL] [Abstract][Full Text] [Related]
9. Muscle-bone interactions in dystrophin-deficient and myostatin-deficient mice.
Montgomery E; Pennington C; Isales CM; Hamrick MW
Anat Rec A Discov Mol Cell Evol Biol; 2005 Sep; 286(1):814-22. PubMed ID: 16078270
[TBL] [Abstract][Full Text] [Related]
10. A canine minidystrophin is functional and therapeutic in mdx mice.
Wang B; Li J; Qiao C; Chen C; Hu P; Zhu X; Zhou L; Bogan J; Kornegay J; Xiao X
Gene Ther; 2008 Aug; 15(15):1099-106. PubMed ID: 18432277
[TBL] [Abstract][Full Text] [Related]
11. Animal models for muscular dystrophy show different patterns of sarcolemmal disruption.
Straub V; Rafael JA; Chamberlain JS; Campbell KP
J Cell Biol; 1997 Oct; 139(2):375-85. PubMed ID: 9334342
[TBL] [Abstract][Full Text] [Related]
12. Involvement of TRPC in the abnormal calcium influx observed in dystrophic (mdx) mouse skeletal muscle fibers.
Vandebrouck C; Martin D; Colson-Van Schoor M; Debaix H; Gailly P
J Cell Biol; 2002 Sep; 158(6):1089-96. PubMed ID: 12235126
[TBL] [Abstract][Full Text] [Related]
13. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy.
Ahmad A; Brinson M; Hodges BL; Chamberlain JS; Amalfitano A
Hum Mol Genet; 2000 Oct; 9(17):2507-15. PubMed ID: 11030755
[TBL] [Abstract][Full Text] [Related]
14. Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse.
Briguet A; Courdier-Fruh I; Foster M; Meier T; Magyar JP
Neuromuscul Disord; 2004 Oct; 14(10):675-82. PubMed ID: 15351425
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of N-glycolylneuraminic acid (Neu5Gc) and cytotoxic T cell (CT) carbohydrate expression in normal and dystrophin-deficient dog and human skeletal muscle.
Martin PT; Golden B; Okerblom J; Camboni M; Chandrasekharan K; Xu R; Varki A; Flanigan KM; Kornegay JN
PLoS One; 2014; 9(2):e88226. PubMed ID: 24505439
[TBL] [Abstract][Full Text] [Related]
16. The sarcolemma in the Large(myd) mouse.
Reed PW; Mathews KD; Mills KA; Bloch RJ
Muscle Nerve; 2004 Nov; 30(5):585-95. PubMed ID: 15389724
[TBL] [Abstract][Full Text] [Related]
17. Constitutive properties, not molecular adaptations, mediate extraocular muscle sparing in dystrophic mdx mice.
Porter JD; Merriam AP; Khanna S; Andrade FH; Richmonds CR; Leahy P; Cheng G; Karathanasis P; Zhou X; Kusner LL; Adams ME; Willem M; Mayer U; Kaminski HJ
FASEB J; 2003 May; 17(8):893-5. PubMed ID: 12670877
[TBL] [Abstract][Full Text] [Related]
18. Coisogenic all-plus-one immunization: a model for identifying missing proteins in null-mutant conditions. Antibodies to dystrophin in mdx mouse after transplantation of muscle from normal coisogenic donor.
Bittner RE; Streubel B; Shorny S; Schaden G; Voit T; Höger H
Neuropediatrics; 1994 Aug; 25(4):176-82. PubMed ID: 7824089
[TBL] [Abstract][Full Text] [Related]
19. Eosinophilia of dystrophin-deficient muscle is promoted by perforin-mediated cytotoxicity by T cell effectors.
Cai B; Spencer MJ; Nakamura G; Tseng-Ong L; Tidball JG
Am J Pathol; 2000 May; 156(5):1789-96. PubMed ID: 10793090
[TBL] [Abstract][Full Text] [Related]
20. Prevention of dystrophic pathology in mdx mice by a truncated dystrophin isoform.
Rafael JA; Sunada Y; Cole NM; Campbell KP; Faulkner JA; Chamberlain JS
Hum Mol Genet; 1994 Oct; 3(10):1725-33. PubMed ID: 7849695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
